The low performance of biopharmaceutical actions versus the widest market for a third consecutive year is an opportunity for investors, according to JPMorgan. The analyst Chris Schott said in the June perspective of the firm to Biofarma that the low performance of the sector dates back to concerns about the tariffs of President Donald Trump and his executive order of the “most favored nation.” The SPDR S&P Biotech ETF (XBI) has withdrawn approximately 7% so far in 2025, while the S&P 500 has obtained a gain of almost 2%. The action of actions is exaggerated, according to Schott, since it expects any impact of this policy to be “manageable.” The valuations are historically depressed, said Schott, which means that the sector already has a price at the worst possible result. “The sector [should be] capable of largely mitigating the impact of tariffs in the middle/long term through manufacturing repatriation and 2) [there’s] Without clear path for MFN [“most favored nation”] To advance without the approval of the Congress (outside the IRA price negotiations), “said Schott. The actions are among the best JPMorgan teams between the group. VERTEX Pharmaceuticals recently approving their newspaper navigation inhibitor. and Bristol Myers Squibb.
